Kenpaullone, 10 mg

STEMCELL Technologies supplies Kenpaullone, a small molecule described as an ATP-competitive inhibitor of several cyclin-dependent kinases (CDKs) as well as glycogen synthase kinase 3 β (GSK-3β). Published data cited in the product documentation report IC₅₀ values of 0.23, 0.4, 0.68, 0.85, and 0.47 µM for GSK-3β, Cdk1/cyclin B, Cdk2/cyclin A, Cdk5/p25, and lymphocyte kinase, respectively. The compound is also known as 9-Bromopaullone (NSC 664704) and is registered under CAS number 142273-20-9.

The product is supplied as a crystalline solid with a chemical formula of C₁₆H₁₁BrN₂O, a molecular weight of 327.2 g/mol, and a stated purity of ≥ 98%. According to the manufacturer, it is stable at -20°C as supplied for 12 months from the date of receipt when protected from prolonged exposure to light. The compound is soluble in DMSO at concentrations up to 30 mM but has low solubility in aqueous media. For use as a cell culture supplement, the stock solution should be diluted into culture medium immediately before use, with final DMSO concentration kept below 0.1% to avoid potential cell toxicity. The product is designated for research use only and not intended for human or animal diagnostic or therapeutic uses.

Kenpaullone has been used across several research areas. In reprogramming studies, it has been reported to replace Klf4 in the generation of induced pluripotent stem (iPS) cells from mouse embryonic fibroblasts transduced with Oct4, Sox2, and c-Myc. In differentiation work, it has been shown to enhance neuronal differentiation in rat and human neural precursor cell cultures and to promote survival of motor neurons derived from mouse embryonic stem cells and from amyotrophic lateral sclerosis (ALS) patient iPS cells. In cancer research, it has been reported to inhibit KLF4 expression and self-renewal in breast cancer stem cells in vitro.